

P 1 VIRAL AND MOLECULAR BIOLOGY

P 1-1	HPV16 minority variants among cervical and anal samples with single HPV16 or multiple HPV types infections	Charpentier C.	France
P 1-2	Detection of cervical human papillomavirus in women attending cervical cancer screening by visual inspection in Côte d'Ivoire	Ouattara A.	Denmark

P 2 EPIDEMIOLOGY AND NATURAL HISTORY

P 2-1	Detection of high-risk HPV DNA in chagasic megaesophagus with and without cancer	Munari F. F.	Brazil
P 2-2	Comparative study of HPV prevalence in glans and urine between the patients with prostate cancer and benign prostatic hyperplasia	Shigehara K.	Japan
P 2-3	HPV prevalence 10 years after vaccine introduction in Germany- design of a population-based study in 20-25 year-old women	Takla A.	Germany
P 2-4	Trends in rates of treated RRP before and after HPV vaccination among New York children	Cass L.	USA
P 2-5	Epidemiology of cervical cancer in a region of Southern Algeria	Benlahrech Z. B.	Algeria
P 2-6	Increasing trends in the incidence of potentially human papillomavirus-associated head and neck cancer in Italy (1988-2012)	Boscolo-Rizzo P.	Italy
P 2-7	Cervical cancer in situ among women aged above 60 who was adequately screened at 50s, and the potential of progressing to invasive cervical cancer	Wang J.	Sweden
P 2-8	Age-specific additional impact of a nonavalent HPV vaccine on precancerous squamous cervical lesions in Spain	Perez S.	Spain
P 2-9	HPV viral load correlations among young, recently-formed heterosexual couples	Wissing M.	Canada
P 2-10	The onset of oral sex, human papillomavirus and oropharyngeal cancers	Laprise C.	Canada
P 2-11	The prognostic role of detection and genotyping of HPV in penile carcinoma	Carneiro Megmar A.S.	Brazil
P 2-12	Recent increase in cervical cancer incidence in Sweden 2014-2015	Andrae B.	Sweden
P 2-13	Screening history and the risk of invasive cervical cancer in women aged 66 and older	Jian-Jhih L.	USA
P 2-14	Pilot prevalence of incidence of 12 genotype of high risk HPV and 2 genotype of low risk HPV in Khorasan Razavi Stateç	Hasanzadeh M.	Iran

P 3 PATHOGENESIS

P 3-1	Presence of HPV in Inverted Papilloma	Elliot A.	Sweden
--------------	---------------------------------------	------------------	---------------

P 4 IMMUNOLOGY

P 4-1	HPV-specific B and T-cell responses in vaccinated and non-vaccinated young women	Pasmans H.	Belgium
P 4-2	Hr-HPV L1, E1, E2, E6, E7 seropositivity does not predict anal HSIL among HIV-positive men who have sex with men	Schim Van Der Loeff M.	Netherlands
P 4-3	Serotype and genetic diversity of human papillomavirus 58 in Italian women with low-grade cytology	Godi A.	UK

P 5 HPV PROPHYLACTIC VACCINES

P 5-1	Human papillomavirus prevalence and genotype distribution in urine samples from vaccinated as compared to non-vaccinated females in Norway	Trogstad L.	Norway
P 5-2	Potential impact of the 9vHPV vaccine in South Korea: an overview	Kim Y.	Korea
P 5-3	Safety and efficacy of a quadrivalent human papillomavirus vaccine against persistent infection and genital diseases in Chinese women during a 78-month follow-up	Wei L.	China
P 5-4	Potential of HPV vaccination in cancer control	Thamsborg L. H.	Denmark
P 5-5	HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway	Feiring B.	Norway
P 5-6	HPV vaccination of adolescent girls is not associated with sexual activity initiation and risky sexual behaviours	Sauvageau C.	Canada
P 5-7	Cross-protective effectiveness of AS04-HPV-16/18 vaccination in reducing cervical HPV infections in adolescent girls- results from a community-randomized trial	Struyf F.	Belgium
P 5-8	HPV	Bah Camara H.	UK
P 5-9	Mother to infant transfer of anti HPV 6 and 11 antibodies upon immunization with the 9VHPV vaccine.	Joshi A.	USA

P 7 IMMUNOTHERAPY - IMMUNO-ONCOLOGY - NEW TREATMENTS

P 7-1	Efficacy of a coriolus versicolor-based vaginal gel to repair cervical mucosa with HPV lesions. Interim analysis results	Serrano L.	Spain
P 7-2	Efficacy of a coriolus versicolor- based vaginal gel to clear HPV. Interim analysis results	Gaslain Y.	Spain
P 7-3	Use of coriolus versicolor-based vaginal gel in patients with precancerous HPV lesions. Interim analysis results	Combalia J.	Spain
P 7-4	Effect of a non-hormonal coriolus versicolor vaginal gel among positive-HPV women with no colposcopy cervical lesions. A pilot study	Emsellem C.	Spain

P 8 HPV TESTING

P 8-1	Papilloplex™ Hr HPV – a novel multiplex assay for detection and genotyping of all 14 Hr HPV types in a single closed-tube real-time PCR reaction	Fu G.	UK
P 8-2	Development and validation of HPV test intended for use in cervical cancer screening “AmpliSens HPV HCR screen-titr-14-FL	Dmitryukova M.	Russia
P 8-3	Mass spectrometry as a reliable high throughput technology for routine HPV diagnostics	Wandernoth P.	Germany
P 8-4	Comparison of mRNA and DNA HPV levels in hrHPV-positive primary screening samples using digital droplet PCR	Lillsunde Larsson G.	Sweden
P 8-5	Population-based HPV Testing Performance: Comparison HC2 and Cervista HPV Testing Assays	Guo M.	USA
P 8-6	Significantly higher risk for high-grade cervical lesions in follow-up biopsy associated with positive Aptima HPV tests than Cobas tests	Ge Y.	USA
P 8-7	HPV test in cytology laboratory practice- a ten year experience	Versa Ostojic D.	Croatia
P 8-8	A highly efficient assay for detection of high-risk HPV E7 proteins in cervical samples	Koch I.	Germany
P 8-9	Xpert®HPV testing on BD-Surepath® medium fixed liquid based cytology specimen: performance evaluation compared to HC2 tests results	Le Van Quyen P.	France

P 8-10	Hr-HPV testing on formalin fixed paraffin embedded (FFPE) samples: performance evaluation of Xpert®HPV versus PCR Inno-lipa® extra II genotyping and P16 IHC on 28 head and neck carcinomas	Fasquelle F.	France
P 8-11	HPV testing for cervical cancer screening: experience in Centro Medicina Laboratorial Germano de Sousa/ Hospital Cuf Descobertas	Albuquerque A.	Portugal
P 8-12	In-house liquid based medium validation for hrHPV detection with Hybrid Capture 2 (HC2), QIAGEN	Nolde N.	USA
P 8-13	Onclarity in the diagnosis of patients with cervical lesion: comparison with HC2 and linear array	Bottari F.	Italy
P 8-14	Comparison of Seegene Anyplex II HPV 28 detection and Abbott Realtime High Risk HPV test on NOVaprep liquid-based cytology media	Hantz S.	France
P 8-15	Methylation of WIF1 gene and microRNA expression in diagnosis of HPV-associated squamous intraepithelial lesions and squamous cervical cancer	Bayramova G.	Russia
P 8-16	Diagnostic excision of cervix in women with persistent HPV infection with no former evidence of CIN in cytology	Aarnio R.	Sweden
P 8-17	Are non-vaccine replacing vaccine genotypes in young women targeted by vaccination programs? A trend analysis from opportunistic screening in Luxembourg	Latsuzbaia A.	Luxembourg

P 9 HPV SCREENING

P 9-1	New scenarios of HPV screening - Georgian experience	Kldiashvili E.	Georgia
P 9-3	Accurate detection of human papillomaviruses by PNA mediated real time PCR using melting curve analysis	Choi B.	Korea
P 9-4	Comparison of p16/Ki67 dual immunocytochemical staining, HPV testing and cytology results obtained in three cytopathology laboratories participating in Slovenian cervical cancer screening program ZORA	Kloboves Prevodnik V.	Slovenia
P 9-5	HPV focal: 48 month colposcopy compliance and time to colposcopy based on referral screen result	Smith L.	Canada
P 9-6	Positive predictive value of HPV screen tests and HPV 16/18 genotyping at baseline and 48 months in the HPV focal trial	Cook D.	Canada
P 9-7	High-grade squamous intraepithelial lesions with negative HPV testing	Duran Arbonés E.	Spain
P 9-8	Randomized health care policy evaluation of organised primary HPV screening of women aged 56-60	Lamin H.	Sweden
P 9-9	Evaluation of the impact of the hr-HPV based cervical cancer screening: results of a four-years experience in a single screening center of Italy	Di Cristofano C.	Italy
P 9-10	Organized cervical cancer-screening program in Brazil: Barretos experience in 18 municipality of São Paulo state	Vazquez F. L.	Brazil
P 9-11	Cervical screening and risk assessment using multiplexed protein assay	Gombrich P.	USA

P 10 SELF-SAMPLING

P 10-1	Cervical cancer and precancerous lesions screening in rural area's women by HPV detection using self-sampled tests	De Paula Pantano N.	Brazil
P 10-2	HPV DNA self-sampling offers a valid tool for cervical cancer screening in Kinshasa, the Democratic Republic of Congo	Ali-Risasi C.	Congo
P 10-3	For high-risk HPV testing the sensitivity of a urine sample equals that of a self-collected vaginal sample	Waldstrøm M.	Denmark
P 10-4	A pilot study of community based self sampling for high risk human papillomavirus test in Chinese population	Chung M. K.	Hong Kong
P 10-5	The cost-effectiveness of HPV self-sampling for non-attenders in a Danish cervical cancer screening program	Asjes C.	USA
P10-6	Evaluation of the Roche Cobas® 6800 HPV assay with Colli-Pee® collected, UCM preserved urine	Vankerckhoven V.	Belgium

P 11 GENOTYPING

P 11-1	The 5-year incidence and clearance of type-specific HPV in a screening cohort in China	Rezhake R.	China
P 11-2	HPV genotyping in ASC-US cytology at Rio de Janeiro, Brazil	Silveira F.	Brazil
P 11-3	A comparison study of the INNO-LiPA and the Linear Array HPV genotyping tests	Ovestad I. T.	Norway
P 11-4	Evaluation of the persistence of HPV genotypes in women treated for CIN2+ lesions	Sandri M. T.	Italy
P 11-5	HPV type specific distribution in women attending routine cervical screening in rural Malawi	Cubie H.	UK
P 11-6	Burden of cervical HPV infection and genotype distribution among women attending two rural health centers in the Gondar region of Ethiopia	Wubneh S. B.	Ethiopia
P 11-7	Genotyping of human papillomavirus in triaging of low-grade cervical cytology	Lecumberri C.	Spain
P 11-8	HPV L1 genetic diversity variants in strains from Northeastern Mexican patients and the discrepancy results obtained by real time PCR	Oyerverides-Munoz M.	Norway

P12 MOLECULAR MARKERS

P 12-1	Diagnostic value of HPV16 and HPV18 viral load and integration status among African women infected with HIV	Didelot-Rousseau M. N.	France
P 12-2	The use of p16/Ki-67 dual staining technology on cervical cytology of patients undergoing a LLETZ procedure	Packet B.	Belgium
P 12-3	Analysis of the influence of p16 in the inter and intra observer concordance in the diagnosis of intraepithelial neoplasia of cervix grade 2 (CIN2)	Forteza A.	Spain
P 12-4	Proteomic composition of cervicovaginal fluid in HPV-associated cervical lesions	Prilepskaya V.	Russia
P 12-5	Detection of cervical (pre)cancer on the basis of cervicovaginal fluid: possibilities for development of a selftest	Verswijvel D.	Belgium
P 12-6	Clinical utility of p16INK4a as a diagnostic adjunct for underlying CIN2+ cervical lesions	Ferrera Boza A.	Honduras
P 12-7	Modern multidisciplinary monitoring of cervical cancer risk	Bohiltca R. E.	Romania
P 12-8	Methylation of inhibitors WNT signaling pathway and HPV types in cervical cancer	Rabelo-Santos S. H.	Brazil
P 12-9	An mRNA panel for triage of HPV positive women with high specificity for detection of clinically relevant cervical disease	Howie S.	UK

P 13 SCREENING METHODS

P 13-1	What is the positive predictive value of high-grade squamous intraepithelial lesion (HSIL) on cytology for the histological diagnosis of cervical intraepithelial neoplasia 2 (CIN2) or more? A systematic review	Bogers J.	Belgium
P 13-2	Comparison of HPV positivity of vaginal samples harvested by gynecologist and patient herself in Japan	Nakashima K.	Japan
P 13-3	Discordant results between oncogenic human papillomavirus RNA and DNA tests in a contesting cervical cancer screening program	Sáez A.	Spain
P 13-4	Upgrading of information system for management and monitoring of Slovenian cervical cancer screening programme	Ivanus U.	Poland
P 13-5	Economic analysis of a strategy to improve cervical cancer screening in Denmark: Cytology with HPV triage vs. primary HPV screening with cytology and CINtec PLUS cytology triage	Kofod M.	Sweden
P 13-6	Role of HPV viral loads in guiding biopsy under colposcopy for ASC-US and HPV positive women	Xu X. Q.	China
P 13-7	Evolution of the cervical cancer screening program in the Western half of the province of Huesca (Spain) between 2010-16	Ramon y Cajal J. M.	Spain
P 13-8	The implementation of HPV based screening in Australia: sustainable workforce implications	Williams V.	Australia
P 13-9	Is a three-year cytological screening cervical cancer safe and is it important for possible early treatment of premalignant intraepithelial lesions?	Živadinovic R.	Serbia
P 13-10	Compare Two Different Usages of the FRD™ for Detecting High Grade Cervical Lesions and Invasive Cancer	Li D.	China
P 13-11	The Significance of the Epithelium Staining Applicator in Cervical Staining with the FRD™	Li D.	China
P 13-12	The diagnostic value of lugol solution, acetic acid, and Pap smear compared to biopsy regarding premalignant and malignant cervical lesions diagnosis in patients in need of colposcopy	Karimi-Zachi M.	Iran

P14 LIQUID BASED CYTOLOGY

P 14-1	HPV analysis improves the PPV of Atypical Glandular Cells	Norman I.	Sweden
---------------	---	------------------	---------------

P 16 METHYLATION

P 16-1	Evaluation of a host DNA methylation panel in a high HPV prevalence cohort	Sousa C.	Portugal
P 16-2	Biological risk factors associated with methylation positive and negative high-grade cervical lesions – clinical study	Cerna K.	Czech Republic

P17 MICROBIOME

P 17-1	The interaction between HPV infection and bacterial microbiota in placenta, cervix and oral mucosa	Tuominen H.	Finland
P 17-2	Vaginal microbiota and PAP smear	Virtanen A.	Finland

P18 SEROLOGY

P 18-1	Development and validation of an optimized HPV competitive Luminex immunoassay (9-PLEX) and HPV IgG antibody detection Luminex immunoassay (9-PLEX) supporting clinical serology testing for Gardasil-9	Nolan K.	USA
--------	---	----------	-----

P19 NEW TECHNOLOGIES

P 19-1	A new generation of validity testing for oncoprotein-based cervical cancer screening	Reichhuber C.	Germany
P 19-2	Establishment of three-dimensional organotypic raft cultures closely mimicking HPV-transformed cervical lesions in an epithelial context	Koehler R.	USA

P 20 DIAGNOSTIC PROCEDURES / MANAGEMENT

P 20-1	Retrospective study of sensitivity, specificity, positive predictive value of cytology in liquid medium, HPV DNA test and genotyping for HPV16, in different cervical cancer screening scenes	Queipo Gutierrez F. J.	Spain
P 20-2	Conization using electrosurgical conization with cold coagulation for cervical intraepithelial neoplasia: a feasible treatment with a low risk of residual disease	Kim S.-Y.	Korea
P 20-3	Evaluation and correlation of primary histopathological diagnosis of targeted biopsy till the final histopathological diagnosis following diagnostic and therapeutic process of leep conization	Pruski D.	Poland
P 20-4	What's behind LSILs?	Rodrigues C.	Portugal
P 20-5	Cytological changes in women under 25 years	Rodrigues C.	Portugal

P 21 COLPOSCOPY

P 21-1	Colposcopy Evaluation at the Time of LEEP May Avoid Unnecessary Treatment	Munmany M.	Spain
P 21-2	Improving clinical practice: the European Federation of Colposcopy quality standards in a colposcopy clinic	Kind A.	Switzerland

P22 CERVICAL NEOPLASIA

P 22-1	A comparison of loop electrosurgical excision procedure using a ring-shaped loop versus a right-angled triangular loop	Kim J. E.	Korea
P 22-2	Post-Coital Bleeding (PCB) as a Predictor for Cervical Pathology : A cross Sectional Study	Agizim R.	Israel
P 22-3	Progression of cervical intraepithelial neoplasia in pregnancy	Grimm D.	Germany
P 22-4	Association between vaginal microbiome, high risk HPV profile, HPV E6/E7 RNA expression and severity of cervical precancerous lesions	Jermakova I.	Latvia
P 22-5	The discovery of a antitumor activity of the alkaloid Erythralin: induction of apoptosis in SiHa cells by arresting the cell cycle at the G2-M phase	Crispim J.	Brazil
P 22-6	Citotoxic and pro apoptotic activities of Croton blanchetianus in human cervical cancer HeLa and SiHa cells	Crispim J.	Brazil

P 24 VULVAR DISEASES AND NEOPLASIA

P 24-1	Vulvar intraepithelial neoplasia-HPV induced pathology?	Mitran M.	Romania
P 24-2	Etiological role of human papillomavirus infection in the development of penile cancer	Sakamoto J.	Japan

P 25 ANAL NEOPLASIA

P 25-1	Factors associated with abnormal anal cytology or HR-HPV anal infection among HIV positive MSM	Rob F.	Czech Republic
P 25-2	HPV genotyping and E6/E7 HPV mRNA expression analyses in anal cytology samples for prevention of HPV-related anal cancer.	Carozzi F.	Italy
P 25-3	Anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma (SCC) in a large urban cohort of HIV-positive individuals living in the United Kingdom: a retrospective data analysis	Vera J.	UK
P 25-4	Human papillomavirus (HPV) and the prognosis of Brazilian patients with anal carcinoma	Saddi V.	Brazil

P 26 ORAL HPV INFECTION

P 26-1	HPV detection in oral cavity of asymptomatic people from North Argentina	Deluca G.	Argentina
P 26-2	Prevalence of HPV-16 and 18 in patients with oral leukoplakia: a preliminary molecular and immunohistochemical study from a Brazilian cohort	Miyahara G. I.	Brazil
P 26-3	DNA damage response as tumor selective radiosensitization strategy for HPV positive and negative head and neck cancers	Dok R.	Belgium

P27 HPV AND OROPHARYNX / HEAD AND NECK CANCER

P 27-1	DNA damage response as tumor selective radiosensitization strategy for HPV positive and negative head and neck cancers	Dok R.	Belgium
P 27-2	Prevalence and impact on survival of HPV and P16 in oropharyngeal cancer other than tonsil or base of tongue cancer	Marklund L.	Sweden
P 27-3	Comparison of Anyplex II HPV 28 and SPF10/DEIA/LiPA25 in FFPE oropharyngeal cancer samples	Pavón Miquel A.	Spain
P 27-4	The prevalence of HPV in head and neck squamous cell cancer tissues of patients from South-Central Poland	Janecka-Widla A.	Poland
P 27-5	Histological subtype of squamous cell carcinoma of head and neck and the presence of HPV assessed by the immunohistochemistry of P16	Collaco Luiz M.	Brazil
P 27-6	TP53 and the association to Afatinib response in HNSCC cell lines	Arantes Lidia M.	Brazil
P 27-7	The role of p16 in the metastasis process of human papillomavirus positive head and neck cancers	Glorieux M.	Belgium
P 27-8	Human papillomavirus DNA detection in fine-needle aspirates as indicator of human papillomavirus-positive oropharyngeal squamous cell carcinoma: a prospective study	Sivars L.	Sweden
P 27-9	The couple management of HPV infection	Puia S.	Romania
P 27-10	Expressed HPV integration events in head and neck cancer: where they occur and their effects on survival and molecular signatures	Sartor M.	USA
P 27-11	The prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal carcinoma.	Thavaraj S.	UK
P 27-12	Frequency and clinical outcome of HPV-driven oropharyngeal carcinoma in North-East Italy	Del Mistro A.	Italy
P 27-13	Prevalence of HPV in branchial cleft cysts and the use of HPV in diagnosis of cystic lesions of the neck	Landin D.	Sweden

P 28 HPV AND ASSOCIATED SKIN DISEASES

P 28-1 E6 proteins of alpha and beta cutaneous HPV types differ in their ability to potentiate Wnt signaling **Sherman L. Israel**

P 29 GENITAL WARTS

P 29-1 Low vaccine coverage but near extinction of HPV 6 and genital warts in young women in Wolfsburg, Germany **Denecke, A. Germany**

P 30 SEXUALLY TRANSMITTED DISEASES AND HIV INFECTION

P 30-1 Accurate and specific detection of 13 genotypes associated with sexually transmitted disease by PNA mediated real time PCR **Jeong E. Korea**

P 30-2 HPV infection among HIV-positive men: A four year revised experience of a diagnosis Laboratory. **Albuquerque A. Portugal**

P 32 ECONOMICS AND MODELLING

P 32-1 Estimating the epidemiological impact and cost effectiveness of the new nonavalent HPV vaccine in Spain **López N. Spain**

P 32-2 Gardasil 9: accelerated reduction in the incidence and costs of HPV-related precancerous lesions and cancers **Olsen J. Denmark**

P 32-3 Cost-effectiveness of cervical cancer screening in Europe- a systematic review with specific interest on risk-adapted strategies **Sroczynski G. Austria**

P 34 HEALTH EDUCATION

P 34-1 A survey of HPV knowledge and attitudes toward HPV vaccination among the middle school students and their parents in China **Feng Xiang X. China**

P 34-2 HPV- What do they know: evaluation of medicine students and health professionals- Valença- Rio de Janeiro/ Brazil **Silveira F. Brazil**

P 36 PUBLIC HEALTH

P 36-1 Well-Child Visits and HPV Vaccination in Preteenagers Aged 11-12 Years during 2007-2015 in the United States **Kothari S. USA**

P 36-2 Acceptability and short-term effects of an HPV vaccination intervention for young gay and bisexual men in the United States **Reiter P. USA**

P 36-3 Digital Interventions to Improve HPV Vaccine Uptake **Woodall W. USA**

P 36-4 Croatian pathway in implementing HPV vaccination (2007.-2017.) **Ferencic Vrban N. Croatia**

P 36-5 HPV prevalence and associated risk factors in women with cervical pre-cancer and cancer in Switzerland at the beginning of the cantonal vaccination programmes: The CIN3+plus study **Spaar A. Switzerland**

P 36-6 HPV vaccine acceptability for daughters among at-risk women in Brazil **Musselwhite L. USA**

P 36-7 Stratifying a screening population into risk categories-personalising a cervical cancer screening programme **Baltzer N. Sweden**